Abstract
Peripheral arterial occlusive disease (PAD) describes vascular disorders associated with ischemia and PAD affects about 8 million people in the United States. Moreover, PADs prevalence can increase dramatically if cardiovascular disease is present. In healthy individuals reducing blood flow through the lower extremity is followed by a physiological process to limit ischemia in the distal tissue. This process is called revascularization and impairing revascularization results in PAD. Studies suggest nitric oxide (NO) maybe involved in the ischemia-dependent hindlimb revascularization process. NO is increased in the ischemic hindlimb and eliminating NO impairs the revascularization process. Moreover, restoring NO improves hindlimb revascularization. NO may be acting through its effects on vascular tone, cell migration, or extracellular matrix degradation. The present review illustrates nitric oxides critical role in the ischemia-induced hindlimb revascularization. Thus, restoring normal NO levels in diseased arteries may represent a viable therapeutic avenue by supplementing exogenous NO or employing therapeutic strategies to either increase NO synthesis and its messengers or decrease NO catabolism.
Keywords: Angiogenesis, arteriogenesis, nitric oxide, revasculatization, peripheral arterial disease
Current Pharmaceutical Design
Title: Nitric Oxide-Dependent Neovascularization Role in the Lower Extremity Disease
Volume: 13 Issue: 35
Author(s): Monica G. Arellano Mendoza, Hilda Vargas Robles, Eunice Romo, Amelia Rios and Bruno Escalante
Affiliation:
Keywords: Angiogenesis, arteriogenesis, nitric oxide, revasculatization, peripheral arterial disease
Abstract: Peripheral arterial occlusive disease (PAD) describes vascular disorders associated with ischemia and PAD affects about 8 million people in the United States. Moreover, PADs prevalence can increase dramatically if cardiovascular disease is present. In healthy individuals reducing blood flow through the lower extremity is followed by a physiological process to limit ischemia in the distal tissue. This process is called revascularization and impairing revascularization results in PAD. Studies suggest nitric oxide (NO) maybe involved in the ischemia-dependent hindlimb revascularization process. NO is increased in the ischemic hindlimb and eliminating NO impairs the revascularization process. Moreover, restoring NO improves hindlimb revascularization. NO may be acting through its effects on vascular tone, cell migration, or extracellular matrix degradation. The present review illustrates nitric oxides critical role in the ischemia-induced hindlimb revascularization. Thus, restoring normal NO levels in diseased arteries may represent a viable therapeutic avenue by supplementing exogenous NO or employing therapeutic strategies to either increase NO synthesis and its messengers or decrease NO catabolism.
Export Options
About this article
Cite this article as:
Arellano Mendoza G. Monica, Robles Vargas Hilda, Romo Eunice, Rios Amelia and Escalante Bruno, Nitric Oxide-Dependent Neovascularization Role in the Lower Extremity Disease, Current Pharmaceutical Design 2007; 13 (35) . https://dx.doi.org/10.2174/138161207782794103
DOI https://dx.doi.org/10.2174/138161207782794103 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bcl-2 Family Proteins Regulate Apoptosis and Epithelial to Mesenchymal Transition by Calcium Signals
Current Pharmaceutical Design Selective Targeting of Liposomes to Macrophages Using a Ligand with High Affinity for the Macrophage Scavenger Receptor Class A
Current Drug Discovery Technologies Growth Factor Therapy in Atherosclerotic Disease-Friend or Foe
Current Pharmaceutical Design Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?
Current Vascular Pharmacology Association Between Polycystic Ovary Syndrome and Metabolic Syndrome
Current Medicinal Chemistry Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design Cardiovascular Effects of Coumarins Besides their Antioxidant Activity
Current Topics in Medicinal Chemistry Human Ascariasis: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Albumin Infusion Therapy in Stroke, Sepsis and the Critically Ill
Current Nutrition & Food Science Adrenomedullin and Oxidative Stress in Vascular Damage and Metabolic Disease
Current Hypertension Reviews Vessel Graft Atherosclerosis in Murine Models
Current Drug Targets Thrombolysis in Ischemic Stroke: Focus on New Treatment Strategies
Recent Patents on Cardiovascular Drug Discovery Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Increasing Bcl-2 and Neuroglubin Expression in Hypoxic Hippocampal Neurons under Hypoxia Preconditioning and in 3-n-butylphalide Treated Cells under Oxygen Glucose Deprivation/Reoxygenation
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) General Anesthetics in Brain Injury: Friends or Foes?
Current Pharmaceutical Design A Systematic Review of a Naturally Occurring Iridoid: Catalpol
Current Bioactive Compounds Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?
Current Topics in Medicinal Chemistry A Murine Model of Vasculitis Induced by Fungal Polysaccharide
Cardiovascular & Hematological Agents in Medicinal Chemistry